Senior Director, Biostatistics

About this role

Company Overview:

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Role Summary:

The Senior Director, Biostatistics provides strategic, technical, and operational leadership for biostatistical activities across one or more clinical development programs. As a senior statistical leader and cross-functional partner, this role leads statistical activities across the drug development lifecycle, including protocol development, authoring of statistical sections of protocols, development of statistical analysis plans, oversight of statistical analyses and deliverables, interpretation and communication of clinical trial results, and preparation of clinical study reports, regulatory documents, manuscripts, and scientific presentations. The Senior Director provides statistical leadership for global regulatory submissions and health authority interactions, ensuring that clinical development programs are supported by scientifically rigorous, operationally feasible, and innovative statistical strategies aligned with program and corporate objectives. The role requires strong communication skills, scientific leadership, self-motivation, and a strategic and forward-thinking approach. Experience in rare disease drug development is desirable.

This role is based in Waltham, MA.

Primary Responsibilities Include:

• Serve as the senior biostatistics lead and subject matter expert for assigned clinical studies, programs, and development initiatives